ASX:ANR

Anatara Lifesciences (ANR) Stock Price, News & Analysis

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
3,950 shs
Average Volume
N/A
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

About Anatara Lifesciences

Anatara Lifesciences Ltd engages in the research, development, and commercialization of evidence-based solutions for gastrointestinal diseases in animals and humans in Australia. It offers Gastrointestinal ReProgramming, a proprietary formulation that combines bromelain with other evidence-based ingredients to address the primary underlying factors associated with human gastrointestinal conditions, such as irritable bowel syndrome and inflammatory bowel disease. The company also provides Detach for the treatment of diarrhea disease in piglets; BONIFF, a revised formulation to dry feed for piglets after weaning; and ANR-pf, a proprietary formulation for poultry in water. Anatara Lifesciences Ltd was incorporated in 2010 and is based in Adelaide, Australia.

ANR Stock News Headlines

Edwards Lifesciences
Eris Lifesciences Ltd.
Better than Bitcoin? The Biotech Stock with 46,751% Potential
4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.
Mega Lifesciences PCL
Zydus Lifesciences Ltd.
Innovation begins with collaboration: Steven Lydeamore
Anatara Lifesciences Ltd (ANR.AX)
Better than Bitcoin? The Biotech Stock with 46,751% Potential
4x Better than Bitcoin Bitcoin would have to go from $68,000 to $314,000 to match the 463% gains we saw with Immunogen in December.
Anatara Lifesciences Ltd
Anatara Lifesciences Ltd (ANR)
Anatara Lifesciences Limited (ANR.AX) Investor Presentation
See More Headlines
Receive ANR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Anatara Lifesciences and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
CIK
N/A
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Net Income
$-1,750,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$1.25 million
Book Value
A$0.01 per share

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
0.65
The 10 Best AI Stocks to Own in 2024 Cover

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Key Executives

  • Dr. David Lionel Brookes F.A.C.I.D. (Age 64)
    FACRRM, FAICD, MBBS, Executive Chairman
    Comp: $168.21k
  • Mr. John Michailidis B.Sc.
    EMBA, M.A.I.C.D., COO & Executive Director
  • Mr. Simon Erskine
    Chief Development Officer
  • Jane Lowe
    Managing Director of IR Department
  • Dr. Stephen Denaro AGIA
    BCom, CA, GradDipApp CG, MAICD, Company Secretary
  • Ms. Hayley van der Meer B Biomed Sc
    Grad Dip Marketing Management, Commercial Manager

ANR Stock Analysis - Frequently Asked Questions

What other stocks do shareholders of Anatara Lifesciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Anatara Lifesciences investors own include Woodside Petroleum (WPL), Temple & Webster Group (TPW), Brompton Oil Split (OSP), Eagle Materials (EXP), BHP Group (BHP) and Ameriprise Financial (AMP).

This page (ASX:ANR) was last updated on 4/25/2024 by MarketBeat.com Staff

From Our Partners